Market Place
Sourcing Support
Moleculin Gets EU Nod To Recruit For MIRACLE Ph3 AML Trial
11 Feb 2025 //
PR NEWSWIRE
Moleculin`s Annamycin Phase 2 AML Data Surpasses Top Competitors
08 Jan 2025 //
#N/A
Moleculin Reports Q2 2024 Results And Provides Corporate Update
14 Aug 2024 //
PR NEWSWIRE
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
10 Jul 2024 //
PR NEWSWIRE
Moleculin US Patent For Annamycin Lipid Delivery Tech
09 May 2024 //
PR NEWSWIRE
Moleculin Presents Positive Annamycin Data
10 Apr 2024 //
PR NEWSWIRE
Moleculin Announces Positive Data in Annamycin MB-106 Phase 1B/2 AML Trial
25 Mar 2024 //
PR NEWSWIRE
Moleculin Announces Positive Interim Data in Annamycin Clinical Trials
13 Nov 2023 //
PR NEWSWIRE
Moleculin Doses First Subjects in Phase 2 Portion of Trial Evaluating Annamycin
02 Oct 2023 //
PR NEWSWIRE
Moleculin Announces Positive Independent Report of No Cardiotoxicity
18 Sep 2023 //
PR NEWSWIRE
Moleculin Successfully Completes 1st Cohort Ph 1b/2 Trial Evaluating Annamycin
02 May 2023 //
PR NEWSWIRE
Italy grants clearance for Moleculin’s Phase I/II leukaemia therapy trial
22 Dec 2022 //
CLINICALTRIALSARENA
Moleculin Concludes PIb and Opens Recruitment in PII Trial of Annamycin
28 Jul 2022 //
PRNEWSWIRE
Moleculin Announces Presentation of Positive Preclinical Annamycin Data at AACR
08 Apr 2022 //
PRNEWSWIRE
Moleculin announces preliminary third cohort interim data in phase 1b/2 trial
29 Dec 2021 //
PHARMABIZ
Moleculin`s Prelim Third Cohort Interim Data in Phase 1b/2 Trial of Annamycin
27 Dec 2021 //
PRNEWSWIRE
Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin
18 Oct 2021 //
PRNEWSWIRE
Moleculin to Extend Dose Escalation in Phase 1/2 Evaluating Annamycin
13 Jul 2021 //
PRNEWSWIRE
Moleculin Biotech begins patient dosing in phase 1b/2 trial of Annamycin
22 Jun 2021 //
PHARMABIZ
Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 of Annamycin
21 Jun 2021 //
PRNEWSWIRE
Moleculin receives grant for Phase IB/II sarcoma trial of Annamycin
09 Feb 2021 //
CLINICALTRIALSARENA
Moleculin Announces Annamycin Receives FDA Orphan Drug Designation
29 Dec 2020 //
PRNEWSWIRE
Moleculin Announces Annamycin Receives FDA Orphan for Soft Tissue Sarcomas
29 Dec 2020 //
PRNEWSWIRE
Moleculin Announces Preclinical Data Confirms of Annamycin in Lung Metastases
24 Jun 2020 //
PRNEWSWIRE
Moleculin Announces Trading Halt
05 May 2020 //
PR NEWSWIRE
WPD Pharm’ Annamycin Drug Candidate Meets Endpoint in Successful U.S. Pha 1 AML
23 Apr 2020 //
PRESS RELEASE
Moleculin Announces Successful Completion of US Phase 1 AML Trial of Annamycin
03 Feb 2020 //
PRESS RELEASE
Moleculin Increases Annamycin Production Due to Positive Clinical Trial
22 Oct 2019 //
PR NEWSWIRE
Moleculin Announces Additional +ve Interim Results, Ph 1/2 Studies of Annamycin
07 May 2019 //
PR NEWSWIRE
Moleculin Receives FDA Approval of Fast Track Designation for Annamycin
18 Apr 2019 //
PR NEWSWIRE
Moleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial
09 Jan 2019 //
GLOBENEWSWIRE
